ECE2024 Eposter Presentations Pituitary and Neuroendocrinology (214 abstracts)
1Ankara Bilkent City Hospital, Endocrinology and Metabolism, Ankara, Turkey; 2Ankara Yıldırım Beyazıt University Faculty Of Medicine, Endocrinology and Metabolism, Ankara; 3Ankara Bilkent City Hospital, Pathology, Cankaya; 4Ankara Bilkent City Hospital, Neurosurgery, Cankaya
Objective: Gonadotroph adenomas are the most common subtype of pituitary adenomas. Rarely, clinical findings may occur due to the secretion of high amounts of biologically active gonadotropins. It may affect platelet activity if there is an excessive increase in the release of estrogen and testosterone or if it is used in pharmacological doses. In this study, we aimed to investigate whether platelet activity indices and coagulation parameters were affected in silent gonadotroph adenomas.
Methods: Patients who operated for a pituitary adenoma in our center between March 2019 and July 2023 were recruited for the study. Presence of thromboembolic disease history, preoperative and postoperative (after the first month) follicle-stimulating hormone (FSH), luteinizing hormone (LH), total testosterone, free testosterone, estradiol (E2), platelet count, mean platelet volume (MPV), platelet distribution width (PDW), international normalized ratio (INR) and activated partial thromboplastin time (aPTT) levels of the patients were recorded.
Results: 25 female patients and 32 male patients were included in the study. We found no statistically significant difference between FSH, LH, testosterone, and E2 levels in both genders preoperative and postoperative periods. No statistically significant difference was observed in MPV, PDW, INR, and aPTT in both genders. None of the patients in the study had a history of thromboembolic events. No thromboembolic event was observed in any patient within the first year of the postoperative period.
Conclusion: Silent gonadotroph adenomas do not affect platelet activity in male and female patients.